Cargando…
Barriers to Treatment Access for Chagas Disease in Mexico
BACKGROUND: According to World Health Organization (WHO) prevalence estimates, 1.1 million people in Mexico are infected with Trypanosoma cruzi, the etiologic agent of Chagas disease (CD). However, limited information is available about access to antitrypanosomal treatment. This study assesses the e...
Autores principales: | Manne, Jennifer M., Snively, Callae S., Ramsey, Janine M., Salgado, Marco Ocampo, Bärnighausen, Till, Reich, Michael R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3798390/ https://www.ncbi.nlm.nih.gov/pubmed/24147169 http://dx.doi.org/10.1371/journal.pntd.0002488 |
Ejemplares similares
-
Access to Chagas disease treatment in the United States after the regulatory approval of benznidazole
por: Yoshioka, Kota, et al.
Publicado: (2020) -
Opportunity Cost for Early Treatment of Chagas Disease in Mexico
por: Ramsey, Janine M., et al.
Publicado: (2014) -
Community resilience and Chagas disease in a rural region of Mexico
por: Rangel, José Antonio Santana, et al.
Publicado: (2016) -
Ecologic Niche Modeling and Potential Reservoirs for Chagas Disease, Mexico.
por: Peterson, A. Townsend, et al.
Publicado: (2002) -
Social Representations and Practices Towards Triatomines and Chagas Disease in Calakmul, México
por: Valdez-Tah, Alba, et al.
Publicado: (2015)